Author Correction: The softness of tumour-cell-derived microparticles regulates their drug-delivery efficiency

Abstract

In the version of this Article originally published, the Supplementary Information file contained two errors. In Supplementary Fig. 17d, the IC 50 values of free DOX for the H22 cells were mistakenly identical to those for the B16-F10 cells. The correct values have now been provided and the associated P values have also been corrected. Additionally, in Supplementary Fig. 23a, the day-6 representative spheroid for the top row (peripheral region) was mistakenly a duplicate of the day-5 representative spheroid for the bottom row (central region). The correct spheroid image has now been provided, and the updated Supplementary Information file is available online.

Tumor-derived microvesicles for cancer therapy

“…Compared with TMVs, TRC-MVs showed higher deformability in infiltration tests in vitro and stronger tumor tissue aggregation and deeper tumor tissue infiltration in vivo , with higher uptake of TRCs. 102…”

Current status of and progress in the treatment of malignant pleural effusion of lung cancer

“…Normally, cellular microparticles in the human body are used to store, transport and digest cellular products and wastes and are important carriers for the transport of various substances (68). Researchers have used autologous tumor cell-derived microparticles (ATMPs) as novel individualized drug carriers (69)(70)(71)(72)(73). In other studies, ATMPs have been used as novel individualized drug carriers to deliver chemotherapeutic drugs to tumor cells in a targeted manner (74-76).…”